Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Feb 12, 2026 · Filed Feb 13, 2026
The boss of Edwards Lifesciences sold $195K of Edwards Lifesciences shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$195,290
Shares × reported transaction price
2 days after results of Feb 10, 2026, 70 days before results of Apr 23, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $76.44 on Feb 12, 2026, 14% above its 52-week low and 12% below its high, after an 11% drop over the previous 30 trading days
52-week range $67.07 (Apr 8, 2025) to $86.94 (Dec 29, 2025), 47% of the way up, from 251 adjusted closes. 30 trading days earlier: $86.20 on Dec 30, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.
Dhimant Patel v. Edwards Lifesciences Corporation, docket 8:24-cv-02221, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +5.0% | +0.7% | +4.4% |
| 30 days | +5.1% | -3.4% | +8.5% |
| 90 days | +5.0% | +8.2% | -3.1% |
| 180 days | +15.8% | +13.2% | +2.6% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
CFO sold ~$431K of Edwards Lifesciences
Scheduled in advanceCFO sold ~$673K of Edwards Lifesciences
Scheduled in advance